Compare NEUP & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NEUP | EVAX |
|---|---|---|
| Founded | 1996 | 2008 |
| Country | United States | Denmark |
| Employees | 8 | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.1M | 25.8M |
| IPO Year | N/A | 2020 |
| Metric | NEUP | EVAX |
|---|---|---|
| Price | $3.65 | $3.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $21.00 | $11.67 |
| AVG Volume (30 Days) | ★ 99.7K | 24.9K |
| Earning Date | 05-23-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $328.20 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.19 | $2.45 |
| 52 Week High | $21.31 | $12.15 |
| Indicator | NEUP | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 29.63 | 41.70 |
| Support Level | N/A | $2.95 |
| Resistance Level | $4.56 | $3.62 |
| Average True Range (ATR) | 0.35 | 0.27 |
| MACD | -0.09 | 0.02 |
| Stochastic Oscillator | 13.76 | 28.89 |
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.